TY - JOUR
T1 - Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma
AU - Palanisamy, Nallasivam
AU - Ateeq, Bushra
AU - Kalyana-Sundaram, Shanker
AU - Pflueger, Dorothee
AU - Ramnarayanan, Kalpana
AU - Shankar, Sunita
AU - Han, Bo
AU - Cao, Qi
AU - Cao, Xuhong
AU - Suleman, Khalid
AU - Kumar-Sinha, Chandan
AU - Dhanasekaran, Saravana M.
AU - Chen, Ying Bei
AU - Esgueva, Raquel
AU - Banerjee, Samprit
AU - Lafargue, Christopher J.
AU - Siddiqui, Javed
AU - Demichelis, Francesca
AU - Moeller, Peter
AU - Bismar, Tarek A.
AU - Kuefer, Rainer
AU - Fullen, Douglas R.
AU - Johnson, Timothy M.
AU - Greenson, Joel K.
AU - Giordano, Thomas J.
AU - Tan, Patrick
AU - Tomlins, Scott A.
AU - Varambally, Sooryanarayana
AU - Rubin, Mark A.
AU - Maher, Christopher A.
AU - Chinnaiyan, Arul M.
N1 - Funding Information:
We thank R.B. Jenkins (Mayo Clinic) for providing prostate cancer tissues with BRAF overexpression for FISH evaluation, R. Morey for assistance in paired-end sequencing and Illumina for technical support. We thank T. Barrette, R. Lonigro, M. Quist, C. Quist and S. Begley for hardware support, sample database maintenance, data curation and maintenance of paired-end sequence data and useful discussions; D. Sanders and M.Vinco for their assistance in procuring gastric cancer samples; and D. Kim, R. Mehra and R. Varambally for providing prostate and melanoma tissue microarray and clinical information from the University of Michigan cohort. We thank D.F. Fries, X. Jiang, L. Wang, R. Jagirdar, N. Kitabayashi and X. Jing for technical assistance, K. Giles for critical reading of the manuscript and A.K. Tewari, Biobank, Weill Cornell Medical College, for providing prostate cancer samples for mutation analysis. This work was supported in part by the US National Institutes of Health (R01CA132874), Early Detection Research Network grant UO1 CA111275, Prostate SPORE grant P50CA69568, the National Center for Integrative Bioinformatics (U54 DA21519-01A1), the National Center for Functional Genomics supported by the Department of Defense (A.M.C.) and R01 CA125612-01 (M.A.R. and F.D.). S.A.T. is supported by a Young Investigator Award from the Prostate Cancer Foundation. A.M.C. is supported by the Doris Duke Charitable Foundation Clinical Scientist Award, a Burroughs Welcome Foundation Award in Clinical Translational Research and the Prostate Cancer Foundation. A.M.C. is an American Cancer Society Research Professor. N.P. is supported by the development award from the Melanoma Research Alliance. C.A.M. currently derives support from the American Association of Cancer Research Amgen Fellowship in Clinical/Translational Research, the Canary Foundation and American Cancer Society Early Detection Postdoctoral Fellowship, and a Prostate Cancer Foundation Young Investigator Award. B.A. is supported by a Genentech Foundation Postdoctoral Fellowship and Young Investigator Award from Expedition Inspiration. T.A.B. is supported by funding from the Prostate Cancer Foundation, a Young Investigator Award and the Canadian Institute of Health Research.
PY - 2010/7
Y1 - 2010/7
N2 - Although recurrent gene fusions involving erythroblastosis virus E26 transformation-specific (ETS) family transcription factors are common in prostate cancer, their products are considered 'undruggable' by conventional approaches. Recently, rare targetable gene fusions involving the anaplastic lymphoma receptor tyrosine kinase (ALK) gene, have been identified in 1-5% of lung cancers, suggesting that similar rare gene fusions may occur in other common epithelial cancers, including prostate cancer. Here we used paired-end transcriptome sequencing to screen ETS rearrangement-negative prostate cancers for targetable gene fusions and identified the SLC45A3-BRAF (solute carrier family 45, member 3-v-raf murine sarcoma viral oncogene homolog B1) and ESRP1-RAF1 (epithelial splicing regulatory protein-1-v-raf-1 murine leukemia viral oncogene homolog-1) gene fusions. Expression of SLC45A3-BRAF or ESRP1-RAF1 in prostate cells induced a neoplastic phenotype that was sensitive to RAF and mitogen-activated protein kinase kinase (MAP2K1) inhibitors. Screening a large cohort of patients, we found that, although rare, recurrent rearrangements in the RAF pathway tend to occur in advanced prostate cancers, gastric cancers and melanoma. Taken together, our results emphasize the key role of RAF family gene rearrangements in cancer, suggest that RAF and MEK inhibitors may be useful in a subset of gene fusion-harboring solid tumors and demonstrate that sequencing of tumor transcriptomes and genomes may lead to the identification of rare targetable fusions across cancer types.
AB - Although recurrent gene fusions involving erythroblastosis virus E26 transformation-specific (ETS) family transcription factors are common in prostate cancer, their products are considered 'undruggable' by conventional approaches. Recently, rare targetable gene fusions involving the anaplastic lymphoma receptor tyrosine kinase (ALK) gene, have been identified in 1-5% of lung cancers, suggesting that similar rare gene fusions may occur in other common epithelial cancers, including prostate cancer. Here we used paired-end transcriptome sequencing to screen ETS rearrangement-negative prostate cancers for targetable gene fusions and identified the SLC45A3-BRAF (solute carrier family 45, member 3-v-raf murine sarcoma viral oncogene homolog B1) and ESRP1-RAF1 (epithelial splicing regulatory protein-1-v-raf-1 murine leukemia viral oncogene homolog-1) gene fusions. Expression of SLC45A3-BRAF or ESRP1-RAF1 in prostate cells induced a neoplastic phenotype that was sensitive to RAF and mitogen-activated protein kinase kinase (MAP2K1) inhibitors. Screening a large cohort of patients, we found that, although rare, recurrent rearrangements in the RAF pathway tend to occur in advanced prostate cancers, gastric cancers and melanoma. Taken together, our results emphasize the key role of RAF family gene rearrangements in cancer, suggest that RAF and MEK inhibitors may be useful in a subset of gene fusion-harboring solid tumors and demonstrate that sequencing of tumor transcriptomes and genomes may lead to the identification of rare targetable fusions across cancer types.
UR - http://www.scopus.com/inward/record.url?scp=77954526989&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954526989&partnerID=8YFLogxK
U2 - 10.1038/nm.2166
DO - 10.1038/nm.2166
M3 - Article
C2 - 20526349
AN - SCOPUS:77954526989
SN - 1078-8956
VL - 16
SP - 793
EP - 798
JO - Nature Medicine
JF - Nature Medicine
IS - 7
ER -